Mannatech, Inc. Hits New 52-Week Low at USD 6.14

Mannatech, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.14 on March 18, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 17.87%, contrasting sharply with the S&P 500's gain of 17.99% during the same period. The company's market capitalization stands at USD 18 million, reflecting its microcap status. Financial metrics indicate a challenging environment, with a negative return on equity of -23.83% and a price-to-book ratio of 2.56. Mannatech has not paid dividends, and its debt-to-equity ratio is reported at -0.40, suggesting a precarious financial position. Recent financial results show a net profit of -USD 2.39 million for the half-year, a decline of 150.84%. Additionally, cash and equivalents have reached a low of USD 13.77 million. Institutional investor participation has also waned, with a 10.19% decrease in stakes over the last quarter, indicating a cautious outlook among larger investors. Overall, Mannatech's performance metrics highlight a period of significant challenges for the company.